Nuvalent (NUVL) Liabilities and Shareholders Equity (2020 - 2026)

Nuvalent's (NUVL) quarterly Liabilities and Shareholders Equity came in at $1.3 billion in Q1 2026, up 20.38% YoY from $1.1 billion in Q1 2025, and down 5.77% on a QoQ basis from $1.4 billion in Q4 2025.

Nuvalent (NUVL) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Nuvalent (NUVL) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $1.3 billion in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 20.38% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 15.87% YoY) and the FY2025 annual result came in at $1.4 billion, up 23.73% from the prior year.
  • Liabilities and Shareholders Equity eased to $1.3 billion in Q1 2026, from $1.4 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q4 2025 to a low of $249.6 million in Q3 2022.
  • A 5-year average of $759.8 million and a median of $708.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity dropped 18.97% — and 2024, when it jumped 179.68%.
  • Tracing NUVL's Liabilities and Shareholders Equity over 5 years: stood at $482.5 million in 2022, then surged by 51.8% to $732.4 million in 2023, then soared by 55.9% to $1.1 billion in 2024, then gained by 23.73% to $1.4 billion in 2025, then decreased by 5.77% to $1.3 billion in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $979.9 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 10.03 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 4.32 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 9.18 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 15.59 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 19.82 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 5.56 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 2.10 Bn
10 Nuvalent 9.10 Bn 9.10 Bn - 1.33 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.33 Bn
Dec 31, 2025 1.41 Bn
Sep 30, 2025 979.91 Mn
Jun 30, 2025 1.04 Bn
Mar 31, 2025 1.11 Bn
Dec 31, 2024 1.14 Bn
Sep 30, 2024 1.19 Bn
Jun 30, 2024 675.23 Mn
Mar 31, 2024 708.47 Mn
Dec 31, 2023 732.38 Mn
Sep 30, 2023 425.08 Mn
Jun 30, 2023 441.95 Mn
Mar 31, 2023 460.99 Mn
Dec 31, 2022 482.46 Mn
Sep 30, 2022 249.56 Mn
Jun 30, 2022 263.02 Mn
Mar 31, 2022 277.04 Mn
Dec 31, 2021 293.82 Mn
Sep 30, 2021 307.97 Mn
Jun 30, 2021 143.50 Mn